Henrik Lindman Selected Research

Henrik Lindman Research Topics

Disease

39	Breast Neoplasms (Breast Cancer) 05/2022 - 01/2002
19	Neoplasms (Cancer) 01/2022 - 01/2002
5	Neoplasm Metastasis (Metastasis) 03/2020 - 01/2008
3	Triple Negative Breast Neoplasms 01/2022 - 06/2017
3	Neutropenia 02/2016 - 12/2009
2	Heart Failure 10/2021 - 02/2014
2	Leukopenia 07/2020 - 04/2011
2	Febrile Neutropenia 01/2018 - 12/2009
1	Myocardial Ischemia (Ischemic Heart Diseases) 10/2021
1	Cardiac Arrhythmias (Arrythmia) 10/2021
1	Ischemic Stroke 10/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2021
1	Transient Ischemic Attack 10/2021
1	Cardiomyopathies (Cardiomyopathy) 10/2021
1	Chronic Disease (Chronic Diseases) 05/2021
1	Fatigue 05/2021
1	Pathologic Complete Response 01/2021
1	Infertility (Sterility) 01/2019
1	Obesity 08/2018
1	Disease Progression 08/2018
1	Overweight 08/2018
1	Inflammation (Inflammations) 01/2018
1	Lung Neoplasms (Lung Cancer) 04/2017
1	Second Primary Neoplasms (Neoplasms, Second) 04/2017
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/2017
1	Left Ventricular Dysfunction 02/2014
1	Noninfiltrating Intraductal Carcinoma (DCIS) 10/2013
1	Heart Diseases (Heart Disease) 04/2013
1	Coronary Disease (Coronary Heart Disease) 04/2013
1	Atrophy 01/2011
1	Hand-Foot Syndrome 12/2009
1	Radiation Pneumonitis 11/2002
1	Unilateral Breast Neoplasms 11/2002

Drug/Important Bio-Agent (IBA)

10	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2007
10	Epirubicin (Ellence)FDA LinkGeneric 01/2022 - 01/2007
8	Docetaxel (Taxotere)FDA Link 01/2022 - 12/2009
7	Capecitabine (Xeloda)FDA Link 01/2022 - 12/2009
6	Fluorouracil (Carac)FDA LinkGeneric 02/2014 - 01/2007
5	AnthracyclinesIBA 01/2022 - 12/2009
5	taxaneIBA 01/2022 - 12/2009
5	Tamoxifen FDA LinkGeneric 10/2021 - 01/2011
5	ErbB Receptors (EGF Receptor)IBA 03/2020 - 05/2014
4	Estrogen ReceptorsIBA 01/2022 - 05/2012
4	Aromatase InhibitorsIBA 10/2021 - 01/2011
4	Trastuzumab (Herceptin)FDA Link 01/2021 - 01/2002
4	Hormones (Hormone)IBA 01/2021 - 06/2017
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2009
4	human ERBB2 proteinIBA 01/2018 - 01/2016
3	ABY-025IBA 03/2020 - 01/2016
3	Phenobarbital (Luminal)FDA Link 11/2019 - 10/2013
3	Pharmaceutical PreparationsIBA 07/2018 - 04/2010
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2016 - 01/2007
2	Biological ProductsIBA 01/2021 - 01/2020
2	68Ga-ABY-025IBA 03/2020 - 01/2016
2	RNA (Ribonucleic Acid)IBA 11/2019 - 01/2019
2	Peptides (Polypeptides)IBA 01/2016 - 01/2009
1	pertuzumabIBA 01/2021
1	Ado-Trastuzumab EmtansineIBA 01/2021
1	SolventsIBA 01/2019
1	EndotoxinsIBA 01/2019
1	RadiopharmaceuticalsIBA 01/2019
1	Fulvestrant (Faslodex)FDA Link 08/2018
1	thiamine triphosphorate (TTP)IBA 08/2018
1	Biocompatible Materials (Biomaterials)IBA 02/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	InterleukinsIBA 01/2018
1	C-Reactive ProteinIBA 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2018
1	SteroidsIBA 06/2017
1	Progesterone Receptors (Progesterone Receptor)IBA 06/2017
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 02/2016
1	IntegrinsIBA 12/2015
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2011
1	thymidine kinase 1IBA 01/2009
1	Etoposide (VP 16)FDA LinkGeneric 06/2008
1	Alkylating AgentsIBA 06/2008
1	Topoisomerase II InhibitorsIBA 06/2008
1	Diphosphonates (Bisphosphonates)IBA 01/2008
1	Pamidronate (Aredia)FDA LinkGeneric 01/2008
1	Protons (Proton)IBA 11/2002

Therapy/Procedure

16	Therapeutics 10/2021 - 01/2007
13	Drug Therapy (Chemotherapy) 05/2022 - 01/2009
10	Adjuvant Chemotherapy 05/2022 - 01/2008
3	Segmental Mastectomy (Lumpectomy) 01/2021 - 11/2002
2	Neoadjuvant Therapy 01/2021 - 01/2002
2	Radiotherapy 01/2018 - 11/2002
2	Aftercare (After-Treatment) 04/2017 - 04/2013
1	Resistance Training 03/2021
1	Combination Drug Therapy (Combination Chemotherapy) 04/2018
1	Intravenous Injections 05/2014